// App-Quantinova.ai

SU-OR32 : Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis

Researchers

Presenter

  • Jayne DavidR.W

Principal Investigators

  • Merkel PeterA

  • Yue Huibin

  • Kelleher CatherineL

  • Schall ThomasJ

  • Bekker Pirow

Medical Centers

  • Addenbrooke's Hospital Cambridge Cambridgeshire United Kingdom

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • ChemoCentryx Inc Mountain View California United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

Biomarkers

  • Complement Component 5a

  • Creatinine

  • Cytochrome C

  • Human albumin

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Oraprine

  • Prednisone

  • Rituximab

  • CCX-168

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved